You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes

    SBC: VASCULAR PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes that will inhibit atherosclerosis. Insulin-like growth factor-I has been implicated in the initiation of the proliferative phase of atherosclerotic lesion development but inhibiting IGF-I receptor activity may lead to tox ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Fast Spectral Imaging Device For Tumor Margin Mapping

    SBC: Zenalux Biomedical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The American Cancer Society estimates that a total of 240,430 new breast cancers were diagnosed in 2007 (178,400 new cases of invasive breast cancer, and 62,030 new cases of in situ breast cancer). Approximately 180,000 of these patients undergo breast conserving surgery (BCS), also called lumpectomy. Multiple recent studies show that a staggering 20-70% of the ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Drug for Septicemia Targets A1 ARs

    SBC: ENDACEA, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Despite the availability of newer antimicrobial agents, improved supportive care, and the introduction of an FDA approved adjunctive therapy for sepsis, (Xigris(r), drotrecogin alfa), the mortality rate for severe sepsis and septic shock of 30-60% remains high. Endacea, Inc. (Research Triangle Park, NC) approaches sepsis with a proprietary diagnostic/biomarker ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Therapy for Staphylococcal Enterotoxin B Poisoning

    SBC: SOYMEDS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a significant human pathogen which can produce a variety of toxins, including the exotoxin, staphylococcal enterotoxin B (SEB). SEB is highly toxic in small doses, and the compact structure of this protein makes it resistant to heat and denaturation. The combination of toxicity and stability caused this toxin to be selected for weaponiz ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. STTR Phase II: Universal Wireless Channel Selection Filter for Enhanced Access to RF Spectrum

    SBC: Physical Devices, Inc.            Topic: ES

    This Small Business Technology Transfer Research (STTR) Phase II project will extend the basic science of linear interference delay effect filters, enabling ultra-wideband tunable RF filters for all types of RF receivers and instrumentation. It will also extend the engineering science of implementing such filters as integrated circuits. And, its distortion filtering aspect will enable enable signa ...

    STTR Phase II 2014 National Science Foundation
  8. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. STTR Phase II: Monolithic Multiwavelength Blue-to-IR LED for Biomedical Diagnostics

    SBC: VALENCELL, INC.            Topic: N/A

    This Small Business Technology Transfer (STTR) Phase II project, in collaboration with North Carolina State University, will develop and validate an innovative, mobile, multiwavelength pulse oximetry module for noninvasive health monitoring of various blood metabolites simultaneously in real time. At the heart of this pulse oximetry module will be a novel multiwavelength emitter having independent ...

    STTR Phase II 2009 National Science Foundation
  10. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government